Related Experiment Video
Updated: Jun 4, 2026

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells
Published on: September 23, 2021
PLA2G12A-driven extracellular vesicle-lipid signaling amplifies pathogenic T cell responses in inflammatory diseases
Chika Mochizuki-Ono1, Yoshitaka Taketomi1, Atsushi Irie2
1Laboratory of Microenvironmental and Metabolic Health Sciences, Center for Disease Biology and Integrative Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.
Extracellular vesicles (EVs) contribute to intercellular communication, yet how EV-driven lipid signaling is regulated in immune responses remains incompletely understood. Here, we show that genetic deficiency or antibody-mediated neutralization of PLA2G12A, a secreted phospholipase A2 (sPLA2) transiently upregulated in activated CD4+ T cells, prevents pathogenic Th17 differentiation and associated diseases including psoriasis and arthritis. PLA2G12A acts on T cell-derived EVs to produce lysophospholipids including the RORγt activator 1-oleoyl-lysophosphatidylethanolamine. Furthermore, these lysophospholipids are converted by autotaxin to lysophosphatidic acid, which amplifies Th17 differentiation via the LPA2 receptor. Moreover, PLA2G12A promotes the secretion and uptake of EVs by Th17 cells and alters their cargo contents. Defective Th17 differentiation by PLA2G12A deficiency is restored by supplementation with PLA2G12A-modified EVs. These results provide a rationale for the sPLA2-EV-lysophospholipid axis as a general mode of sPLA2 action and suggest that targeting PLA2G12A may be useful for the treatment of Th17-related or possibly other inflammatory diseases.
Extracellular vesicles (EVs) contribute to intercellular communication, yet how EV-driven lipid signaling is regulated in immune responses remains incompletely understood. Here, we show that genetic deficiency or antibody-mediated neutralization of PLA2G12A, a secreted phospholipase A2 (sPLA2) transiently upregulated in activated CD4+ T cells, prevents pathogenic Th17 differentiation and associated diseases including psoriasis and arthritis. PLA2G12A acts on T cell-derived EVs to produce lysophospholipids including the RORγt activator 1-oleoyl-lysophosphatidylethanolamine. Furthermore, these lysophospholipids are converted by autotaxin to lysophosphatidic acid, which amplifies Th17 differentiation via the LPA2 receptor. Moreover, PLA2G12A promotes the secretion and uptake of EVs by Th17 cells and alters their cargo contents. Defective Th17 differentiation by PLA2G12A deficiency is restored by supplementation with PLA2G12A-modified EVs. These results provide a rationale for the sPLA2-EV-lysophospholipid axis as a general mode of sPLA2 action and suggest that targeting PLA2G12A may be useful for the treatment of Th17-related or possibly other inflammatory diseases.
Related Concept Videos
Intracellular Signaling Cascades
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Intracellular Signaling Affects Focal Adhesions
Some...
Amplifying Signals via Second Messengers
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
IP3/DAG Signaling Pathway

